DK2407154T3 - Formuleringer af 14-epi-analoger af D-vitamin - Google Patents
Formuleringer af 14-epi-analoger af D-vitaminInfo
- Publication number
- DK2407154T3 DK2407154T3 DK11173836.5T DK11173836T DK2407154T3 DK 2407154 T3 DK2407154 T3 DK 2407154T3 DK 11173836 T DK11173836 T DK 11173836T DK 2407154 T3 DK2407154 T3 DK 2407154T3
- Authority
- DK
- Denmark
- Prior art keywords
- vitamin
- formulations
- epi analogues
- epi
- analogues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/836,974 US20120015913A1 (en) | 2010-07-15 | 2010-07-15 | Formulations of 14-EPI-Analogues of Vitamin D |
| EP10305783A EP2407152A1 (en) | 2010-07-15 | 2010-07-15 | Formulations of 14-epi-analogues of vitamin D |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2407154T3 true DK2407154T3 (da) | 2013-03-04 |
Family
ID=44281019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11173860.5T DK2407155T3 (da) | 2010-07-15 | 2011-07-13 | Formuleringer af inecalcitol |
| DK11173836.5T DK2407154T3 (da) | 2010-07-15 | 2011-07-13 | Formuleringer af 14-epi-analoger af D-vitamin |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11173860.5T DK2407155T3 (da) | 2010-07-15 | 2011-07-13 | Formuleringer af inecalcitol |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2407154B1 (da) |
| JP (2) | JP5836373B2 (da) |
| KR (2) | KR101821441B1 (da) |
| CN (2) | CN103096877B (da) |
| AU (2) | AU2011278352B2 (da) |
| BR (2) | BR112013000941A2 (da) |
| CA (2) | CA2805203A1 (da) |
| DK (2) | DK2407155T3 (da) |
| ES (2) | ES2398640T3 (da) |
| HR (2) | HRP20130093T1 (da) |
| IL (2) | IL224191A (da) |
| MX (1) | MX2013000539A (da) |
| NZ (2) | NZ606678A (da) |
| PL (2) | PL2407155T3 (da) |
| PT (2) | PT2407154E (da) |
| SG (2) | SG187072A1 (da) |
| SI (2) | SI2407154T1 (da) |
| WO (3) | WO2012007512A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120015913A1 (en) | 2010-07-15 | 2012-01-19 | Delansorne Remi | Formulations of 14-EPI-Analogues of Vitamin D |
| PL2407155T3 (pl) * | 2010-07-15 | 2013-05-31 | Hybrigenics Sa | Formulacje inekalcytolu |
| EP2908827A4 (en) * | 2012-10-19 | 2016-08-31 | Celus Pharmaceuticals Inc | VITAMIN D ANALOGUE FOR THE TREATMENT OF A NEUROLOGICAL DISEASE |
| KR20190017873A (ko) * | 2016-06-08 | 2019-02-20 | 썬리겐 헬쓰케어 아게 | 홀수의 탄소 원자를 갖는 지질 및 제약 조성물 또는 영양 보충제로서의 그의 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2166898C (en) | 1993-07-09 | 2004-09-07 | Roger Bouillon | Novel structural analogues of vitamin d |
| JPH10111593A (ja) * | 1996-10-04 | 1998-04-28 | Asahi Optical Co Ltd | 複写機の変倍光学装置 |
| US5936105A (en) | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| GB0305332D0 (en) | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
| US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
| US7332482B2 (en) | 2003-09-24 | 2008-02-19 | Bioxell S.P.A. | Method for treating benign prostatic hyperplasia |
| GB0423091D0 (en) * | 2004-10-19 | 2004-11-17 | Leuven K U Res & Dev | Bioactive vitamin d analogues |
| US20070093458A1 (en) * | 2005-07-18 | 2007-04-26 | Anchel Schwartz | Preparation of paricalcitol and crystalline forms thereof |
| US20080145411A1 (en) * | 2006-10-06 | 2008-06-19 | Kaneka Corporation | Composition of high absorbability for oral administration comprising oxidized coenzyme q10 |
| JP2010111593A (ja) * | 2008-11-04 | 2010-05-20 | Teijin Pharma Ltd | １４−エピ−１９−ノルプレビタミンｄ３誘導体 |
| CN102448466A (zh) * | 2009-05-20 | 2012-05-09 | 混合基因股份公司 | 伊奈骨化醇的新治疗应用 |
| PL2407155T3 (pl) * | 2010-07-15 | 2013-05-31 | Hybrigenics Sa | Formulacje inekalcytolu |
-
2011
- 2011-07-13 PL PL11173860T patent/PL2407155T3/pl unknown
- 2011-07-13 BR BR112013000941A patent/BR112013000941A2/pt not_active Application Discontinuation
- 2011-07-13 PT PT111738365T patent/PT2407154E/pt unknown
- 2011-07-13 CN CN201180043277.7A patent/CN103096877B/zh not_active Expired - Fee Related
- 2011-07-13 AU AU2011278352A patent/AU2011278352B2/en not_active Ceased
- 2011-07-13 DK DK11173860.5T patent/DK2407155T3/da active
- 2011-07-13 SG SG2013002910A patent/SG187072A1/en unknown
- 2011-07-13 WO PCT/EP2011/061973 patent/WO2012007512A1/en active Application Filing
- 2011-07-13 BR BR112013000930A patent/BR112013000930A2/pt not_active Application Discontinuation
- 2011-07-13 JP JP2013519097A patent/JP5836373B2/ja not_active Expired - Fee Related
- 2011-07-13 PT PT111738605T patent/PT2407155E/pt unknown
- 2011-07-13 KR KR1020137003060A patent/KR101821441B1/ko active IP Right Grant
- 2011-07-13 CN CN2011800432762A patent/CN103096876A/zh active Pending
- 2011-07-13 EP EP11173836A patent/EP2407154B1/en not_active Not-in-force
- 2011-07-13 CA CA2805203A patent/CA2805203A1/en not_active Abandoned
- 2011-07-13 PL PL11173836T patent/PL2407154T3/pl unknown
- 2011-07-13 JP JP2013519093A patent/JP5836372B2/ja not_active Expired - Fee Related
- 2011-07-13 EP EP11173860A patent/EP2407155B1/en not_active Not-in-force
- 2011-07-13 MX MX2013000539A patent/MX2013000539A/es active IP Right Grant
- 2011-07-13 SG SG2013002902A patent/SG187071A1/en unknown
- 2011-07-13 NZ NZ606678A patent/NZ606678A/en not_active IP Right Cessation
- 2011-07-13 WO PCT/EP2011/061984 patent/WO2012007517A1/en active Application Filing
- 2011-07-13 SI SI201130012T patent/SI2407154T1/sl unknown
- 2011-07-13 SI SI201130021T patent/SI2407155T1/sl unknown
- 2011-07-13 AU AU2011278346A patent/AU2011278346B2/en not_active Ceased
- 2011-07-13 DK DK11173836.5T patent/DK2407154T3/da active
- 2011-07-13 CA CA2805198A patent/CA2805198C/en not_active Expired - Fee Related
- 2011-07-13 ES ES11173836T patent/ES2398640T3/es active Active
- 2011-07-13 KR KR1020137003059A patent/KR101821440B1/ko active IP Right Grant
- 2011-07-13 NZ NZ606679A patent/NZ606679A/en not_active IP Right Cessation
- 2011-07-13 ES ES11173860T patent/ES2401715T3/es active Active
- 2011-07-15 WO PCT/EP2011/062127 patent/WO2012007570A2/en active Application Filing
-
2013
- 2013-01-13 IL IL224191A patent/IL224191A/en active IP Right Grant
- 2013-01-13 IL IL224192A patent/IL224192A/en active IP Right Grant
- 2013-02-04 HR HRP20130093AT patent/HRP20130093T1/hr unknown
- 2013-03-19 HR HRP20130237AT patent/HRP20130237T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201700043B (it) | Formulazioni di bendamustina | |
| DK3725778T3 (da) | Formuleringer af enzalutamid | |
| DK2648809T3 (da) | Naturlige formuleringer | |
| DK2498756T3 (da) | Tabletformuleringer af neratinibmaleat | |
| DK3170508T3 (da) | Vaccineformuleringer | |
| DK2567524T3 (da) | Reduktion af protokolspild | |
| DK2640893T4 (da) | Sammensætninger | |
| DK2571517T4 (da) | Langtidsvirkende formuleringer af insuliner | |
| DK3156056T3 (da) | Farmaceutiske sammensætninger der består af sorbitanestere | |
| DK2603232T3 (da) | Stabile formuleringer af linaclotid | |
| CO6930368A2 (es) | Composiciones de yodo-povidona estable | |
| GT201200303A (es) | Formulaciones farmacéuticas | |
| DK2633006T3 (da) | Fremstilling af fornybart bio-destillat | |
| FI9350U1 (fi) | Ravintoformulaatioita | |
| DK3831406T3 (da) | Stabile formuleringer af Neisseria-Meningitidis-RLP2086-antigener | |
| BR112013025845A2 (pt) | formulações com viscosidade reduzida | |
| CO6900117A2 (es) | Formulaciones peptídicas de liberación controlada | |
| SMT201600380B (it) | Formulazioni di darunavir | |
| CO6940426A2 (es) | Formulaciones farmacéuticas | |
| DK2648696T3 (da) | Ny indgivelsesform af racecadotril | |
| DK2800572T3 (da) | Sammensætning af ellagitannin-rige ekstrakter | |
| BR112013014612A2 (pt) | composições moc | |
| CO6801722A2 (es) | Composiciones farmacéuticas | |
| DK2571843T3 (da) | Forbedret fremstilling af chalcon-derivater | |
| CO6801717A2 (es) | Composiciones nasales de vitamina b12 |